| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,6 Md € | +9.8% | 4,2 Md € | +32.6% | 3,2 Md € | -3.6% | 3,3 Md € | -4.0% | 3,4 Md € | -11.4% | 3,9 Md € | +19.3% | 3,2 Md € | +20.6% | 2,7 Md € | +15.3% | 2,3 Md € | +4.7% | 2,2 Md € | +19.9% | 1,9 Md € | +44.6% | 1,3 Md € | +11.8% | 1,1 Md € | +6.6% | 1,1 Md € | +0.0% | 1,1 Md € | -6.7% | 1,2 Md € | +87.7% | 615,9 M € | -51.7% | 1,3 Md € | |
| EBITDA | 451,1 M € | -59.5% | 1,1 Md € | +23.7% | 899,9 M € | -20.3% | 1,1 Md € | +44.7% | 780,8 M € | +3.8% | 752,0 M € | -7.3% | 811,3 M € | +33.3% | 608,9 M € | -3.4% | 630,6 M € | +51.2% | 417,0 M € | +6.3% | 392,2 M € | +46.9% | 267,0 M € | -56.2% | 609,0 M € | +29.9% | 468,7 M € | -12.8% | 537,6 M € | -19.3% | 666,6 M € | +204.9% | 218,6 M € | -72.6% | 797,0 M € | |
| Operating profit | 334,7 M € | -67.4% | 1,0 Md € | +17.7% | 872,8 M € | -11.5% | 985,7 M € | +47.4% | 668,9 M € | +5.1% | 636,7 M € | -10.3% | 709,8 M € | +45.1% | 489,2 M € | -10.3% | 545,4 M € | +59.6% | 341,8 M € | +10.3% | 309,8 M € | +60.5% | 193,0 M € | +433.3% | -57,9 M € | +63.0% | -156,6 M € | -253.9% | -44,3 M € | -153.2% | 83,1 M € | +126.6% | -312,5 M € | -256.5% | 199,7 M € | |
| Profit/loss | 4,2 Md € | +347.5% | 947,4 M € | +1.0% | 938,1 M € | -1.1% | 948,1 M € | +54.8% | 612,6 M € | +6.6% | 574,8 M € | +29.4% | 444,3 M € | +1.1% | 439,6 M € | -22.4% | 566,7 M € | +15.2% | 491,7 M € | +1711.0% | -30,5 M € | -188.9% | 34,3 M € | -47.8% | 65,8 M € | +125.7% | -256,5 M € | -948.0% | -24,5 M € | -111.3% | 217,2 M € | +212.3% | -193,3 M € | +2.2% | -197,8 M € | |
| Equity | 16,2 Md € | +31.0% | 12,4 Md € | +5.1% | 11,8 Md € | +5.2% | 11,2 Md € | +15.1% | 9,7 Md € | +4.4% | 9,3 Md € | +210.6% | 3,0 Md € | +27.6% | 2,4 Md € | +23.0% | 1,9 Md € | +42.1% | 1,3 Md € | +116.9% | 621,2 M € | -4.7% | 651,8 M € | +5.6% | 617,4 M € | +11.9% | 551,6 M € | -31.7% | 808,1 M € | -3.0% | 832,6 M € | +315.4% | 200,5 M € | +475.2% | 34,8 M € | |
| Total assets | 20,7 Md € | +26.4% | 16,4 Md € | +8.0% | 15,2 Md € | +4.3% | 14,6 Md € | +24.4% | 11,7 Md € | +0.4% | 11,7 Md € | +105.6% | 5,7 Md € | -1.3% | 5,7 Md € | +22.2% | 4,7 Md € | +11.4% | 4,2 Md € | +8.8% | 3,9 Md € | +0.3% | 3,9 Md € | -15.9% | 4,6 Md € | +11.6% | 4,1 Md € | -11.5% | 4,7 Md € | +9.4% | 4,3 Md € | +11.3% | 3,8 Md € | -4.5% | 4,0 Md € | |
| Cash | 7,9 M € | -28.8% | 11,1 M € | +43.9% | 7,7 M € | -54.4% | 16,8 M € | +2272.0% | 710,3 k € | -46.5% | 1,3 M € | -71.3% | 4,6 M € | -86.0% | 33,1 M € | +93.5% | 17,1 M € | +133.3% | 7,3 M € | -58.3% | 17,6 M € | +152.3% | 7,0 M € | -99.6% | 1,8 Md € | +46009.0% | 4,0 M € | +91.8% | 2,1 M € | +78.4% | 1,2 M € | -49.6% | 2,3 M € | -47.1% | 4,4 M € | |
| Debts | 4,4 Md € | +11.8% | 3,9 Md € | +18.1% | 3,3 Md € | +0.2% | 3,3 Md € | +73.9% | 1,9 Md € | -13.7% | 2,2 Md € | -15.5% | 2,6 Md € | -22.2% | 3,3 Md € | +21.6% | 2,7 Md € | -2.7% | 2,8 Md € | -12.4% | 3,2 Md € | +2.7% | 3,1 Md € | -14.9% | 3,7 Md € | +14.5% | 3,2 Md € | -6.7% | 3,4 Md € | +20.7% | 2,9 Md € | -2.5% | 2,9 Md € | -1.1% | 3,0 Md € | |
| Staff | 1 960,6 | 1 746,4 | 1 464,4 | 1 371,1 | 1 326,1 | 1 266,2 | 1 079,1 | 1 024 | 983,8 | 935,9 | 897,9 | 1 200,3 | 1 825 | 1 809,9 | 1 745,2 | 1 754,6 | 1 959,3 | 2 308,5 | ||||||||||||||||||
Public limited company · Anderlecht · incorporated on 01/02/1968 · 1 960,6 ETP
Public limited company profitable and well capitalised. Cash position declining (-28.8%).
Solid counterparty for a standard engagement.
| Unit no. | Name | Location |
|---|---|---|
| 2037631587 | UCB PHARMA | Allée de la Recherche 60, 1070 Anderlecht |
| 2159107459 | UCB PHARMA | Chemin du Foriest /, 1420 Braine-l'Alleud |
| 2342005216 | UCB Pharma | Gaston Geenslaan 14, 3001 Leuven |
UCB PHARMA is a Public limited company incorporated in 1968. Its main activity is: Fabrication de médicaments. Its registered office is in Anderlecht. It employs on average 1 960,6 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette